Regeneron Pharmaceuticals, Inc.
REGN
$768.29
$1.630.21%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.09% | -1.64% | 3.17% | 16.63% | 11.61% |
| Total Depreciation and Amortization | 12.59% | 11.84% | 12.56% | 13.80% | 14.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -520.31% | -66.75% | 35.26% | -133.15% | -54.29% |
| Change in Net Operating Assets | 186.14% | 174.21% | 65.55% | -980.76% | -557.07% |
| Cash from Operations | 12.63% | 19.39% | 16.53% | -16.58% | -3.78% |
| Capital Expenditure | -18.85% | -5.15% | -19.95% | -26.25% | -5.19% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | 80.00% | -64.77% | 80.80% | 69.95% | 69.95% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 115.89% | 117.48% | 111.41% | 118.28% | 28.85% |
| Cash from Investing | 74.51% | 82.71% | 76.12% | 97.12% | 22.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.60% | -86.67% | -74.09% | -37.14% | 27.92% |
| Repurchase of Common Stock | -9.31% | -27.06% | -41.05% | -46.34% | -23.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.16% | 69.16% | -- | -- | -- |
| Cash from Financing | -68.84% | -169.39% | -210.41% | -134.90% | -22.93% |
| Foreign Exchange rate Adjustments | 142.86% | -150.00% | 237.50% | 144.44% | -75.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 355.10% | 437.80% | 506.51% | 136.63% | 34.80% |